TrialRMD open2019

Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study.

Xenofon Baraliakos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.